EU panel recommends against nod for Puma Biotech’s breast cancer drug
(Reuters) – A European Medicines Agency (EMA) panel on Friday recommended against approving Puma Biotechnology’s lead breast cancer drug, an outcome the U.S drugmaker had signaled last month. The EMA said the Committee for Medicinal Products for Human Use (CHM... More »
